Spravato can be used in conjunction with oral anti-depressants primarily for patients who have tried and received no benefits from other anti-depressant treatments.
Spravato (esketamine) is a recently released treatment for treatment-resistant depression (TRD). It is administered as a nasal spray, typically in conjunction with oral anti-depressants. Clinical studies have shown most patients who have TRD experienced a reduction in depression and suicidal ideation within just 24 hours from start of treatment, continuing to improve through the end of a four-week period. Sixty percent of patients have shown to have symptoms of depression reduced with continual treatment -- even after 80 weeks.
Spravato is given as an intranasal spray, which can be self-administered after consultation. For the first four weeks (induction phase), Spravato is to be taken twice weekly, then is only required to be administered once weekly or once every other week (maintenance phase).
Frequently Asked Questions
A low dose of Spravato will be administered via intra-nasal spray. After five minutes another small dose will be administered. Your provider will monitor you for a two hour waiting period. We encourage you to wear eye shades, listen to relaxing music, and focus inward during this time.
Spravato's side effects wear off quite quickly; you will be able to return home about 2 hours after treatment is complete. Patients are required to have another person drive them home. You should not drive until the next day after a restful sleep.